Author:
Lu Wenbin,Chen Lijuan,Wang Yu,Yao Yuyu,Fu Cong,Zuo Pengfei,Ma Genshan
Funder
AstraZeneca Pharmaceutical Co., Ltd.
National Natural Science Foundation of China
LJ
Subject
Pharmacology (medical),General Medicine
Reference39 articles.
1. Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multi-center study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation;Naccarelli;J Interv Card Electrophysiol,2014
2. Improved understanding of the pathophysiology of atrial fibrillation through the lens of discrete pathological pathways;Balouch;Glob Cardiol Sci Pract,2014
3. New oral anticoagulants in patients with non-valvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness;Mani;Drug Des Devel Ther,2014
4. Statin therapy for primary prevention of atrial fibrillation: guided by CHADS2/CHA2DS2VASc score;Hung;Korean Circ J,2014
5. Triple antithrombotic therapy with aspirin, a thienopyridine derivative plus oral anticoagulation in patients with atrial fibrillation undergoing coronary stenting;Pipilis;Hellenic J Cardiol,2010
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献